Fine Tuning Therapeutic Targeting of the Sphingolipid Biosynthetic Pathway to Treat Atherosclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|4|2|151-154

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.4, Iss.2, 2006-04, pp. : 151-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 4, Iss. 2, 2009-01 ,pp. : 76-87

Bentham Science Publishers

Access to resources Recommend Favorite

Sphingolipid signalling: a potential pathway for TNF induced preconditioning

By Lecour S.   Sack M.N.   Opie L.H.  

Annales de Cardiologie et d'Angeiologie, Vol. 52, Iss. 6, 2003-12 ,pp. : 363-369

Elsevier

Access to resources Recommend Favorite

MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis

By  

Current Vascular Pharmacology, Vol. 13, Iss. 3, 2015-05 ,pp. : 405-412

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Options to Treat Autoimmune Hepatitis in 2009

By  

Digestive Diseases, Vol. 28, Iss. 1, 2010-05 ,pp. : 93-98

Karger

Access to resources Recommend Favorite

Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 98-104

Bentham Science Publishers

Access to resources Recommend Favorite